Difference between revisions of "Team:WPI Worcester/HP/Gold"

(Undo revision 428944 by Mrgoogins (talk))
 
(31 intermediate revisions by 5 users not shown)
Line 5: Line 5:
  
 
<div class="column full_size">
 
<div class="column full_size">
 +
<img align="center" src="https://static.igem.org/mediawiki/2016/9/9d/T--WPI_Worcester--Gold.jpeg" style="width:100%;height:450px"/>
 +
<br>
 +
<br>
  
 +
<p><img border="0" align="left" hspace="10" src="https://static.igem.org/mediawiki/2016/2/24/T--WPI_Worcester--Integrated.jpeg" style="width:250px;height:340;">
 +
<br><br><b> Integrated Human Practices </b> <br>
 +
The main goal of our integrated human practices approach this year was to take into consideration the ethics and safety concerns of our project. Throughout the design process, the team interviewed several professors, researchers and graduate students in the fields of RNA therapeutics and CRISPR technology in order to understand their concerns about the team's design. From these conversations, three main concerns arose: the permanence of current gene editing systems, the need for tunability, and public opinion of gene therapy. Each concern was then incorporated into the design of the project. The system was designed to target mRNA to address the permanency aspect of the system. The system was made tunable by incorporating a tetracycline transactivator element that can be controlled by the use of doxycycline. Finally, the team decided that the best approach to ensuring public acceptance of the system was through efficient public education about biological concepts. Through in depth research, the team was able to develop and execute many activities to educate the community about current and future biological ideas. <br>
 +
<center> For more information see our Integrated Human Practices page <a href="https://2016.igem.org/Team:WPI_Worcester/Integrated_Practices">here.</a></center></p>
 +
<br>
 +
<br>
 
<br>
 
<br>
<table>
 
      <tr>
 
          <td>Integrated Human Practices</td>
 
          <td>This summer we held multiple interviews with scientists and graduate students that have worked with CRISPR and/or RNA before. We listen to their ideas and tried to incorporate solutions to any possible concerns they had into our project. We also talked about public perception of out project and how to explain RNA editing to the public.</td>
 
          <td>For more information see our Integrated Human Practices page <a href="https://2016.igem.org/Team:WPI_Worcester/Integrated_Practices">here.</a></td>
 
      </tr>
 
      <tr>
 
          <td> Improve a previous part or project</td>
 
          <td>Improve the function OR characterization of an existing BioBrick Part or Device and enter this information in the Registry. Please see the Registry help page on how to document a contribution to an existing part. This part must NOT be from your 2016 part number range.</td>
 
          <td>See the part we helped to document <a href="http://parts.igem.org/Part:BBa_J33201">here.</a> </td>
 
      </tr>
 
      <tr>
 
          <td>Proof of concept</td>
 
          <td>Demonstrate a functional proof of concept of your project. Your proof of concept must consist of a BioBrick device; a single BioBrick part cannot constitute a proof of concept.</td>
 
          <td>What we did here</td>
 
      </tr>
 
      <tr>
 
          <td>Demonstrate your work</td>
 
          <td>Show your project working under real-world conditions. To achieve this criterion, you should demonstrate your whole system, or a functional proof of concept working under simulated conditions in the lab.</td>
 
          <td>what we did here</td>
 
      </tr>
 
   
 
 
<p>iGEM teams are unique and leading the field because they "go beyond the lab" to imagine their projects in a social/environmental context, to better understand issues that might influence the design and use of their technologies.</p>
 
<p>Teams work with students and advisors from the humanities and social sciences to explore topics concerning ethical, legal, social, economic, safety or security issues related to their work. Consideration of these Human Practices is crucial for building safe and sustainable projects that serve the public interest. </p>
 
  
 +
<p><img border="0" align="left" hspace="10" src="https://static.igem.org/mediawiki/2016/9/9b/T--WPI_Worcester--Improve.jpeg" style="width:250px;height:340;">
 +
<br><br><b> Improve a Previous Part or Project </b> <br>
 +
Our team improved the characterization of the BioBrick Part BBa_K1321005 with a simple Arsenic Amount Test Kit. We then photographed the test strips and analyzed the images to quantitatively provide characterization.
 +
See the part we helped to document <a href="http://parts.igem.org/Part:BBa_K1321005">here.</a> The measurement details can be found on the <a href="https://2016.igem.org/Team:WPI_Worcester/Measurement">Measurement</a> page. The experiment was performed by growing dh5alpha cells that contained the biobrick plasmids of the parts. Liquid cultures were then grown from these cells overnight. They were then back diluted to an optical density of 0.1 with sodium arsenic. These cultures were grown for four hours then were tested with the provided Arsenic Amount Test Kit. Images of the test strips were then taken and the coloration between the test strips and the test kit to determine efficiency of the BBa_K1321004 part. These tests were repeated three times to confirm the result.</p> 
 +
<br>
 +
<br>
 +
<br>
  
 
</div>
 
</div>

Latest revision as of 02:52, 20 October 2016





Integrated Human Practices
The main goal of our integrated human practices approach this year was to take into consideration the ethics and safety concerns of our project. Throughout the design process, the team interviewed several professors, researchers and graduate students in the fields of RNA therapeutics and CRISPR technology in order to understand their concerns about the team's design. From these conversations, three main concerns arose: the permanence of current gene editing systems, the need for tunability, and public opinion of gene therapy. Each concern was then incorporated into the design of the project. The system was designed to target mRNA to address the permanency aspect of the system. The system was made tunable by incorporating a tetracycline transactivator element that can be controlled by the use of doxycycline. Finally, the team decided that the best approach to ensuring public acceptance of the system was through efficient public education about biological concepts. Through in depth research, the team was able to develop and execute many activities to educate the community about current and future biological ideas.

For more information see our Integrated Human Practices page here.






Improve a Previous Part or Project
Our team improved the characterization of the BioBrick Part BBa_K1321005 with a simple Arsenic Amount Test Kit. We then photographed the test strips and analyzed the images to quantitatively provide characterization. See the part we helped to document here. The measurement details can be found on the Measurement page. The experiment was performed by growing dh5alpha cells that contained the biobrick plasmids of the parts. Liquid cultures were then grown from these cells overnight. They were then back diluted to an optical density of 0.1 with sodium arsenic. These cultures were grown for four hours then were tested with the provided Arsenic Amount Test Kit. Images of the test strips were then taken and the coloration between the test strips and the test kit to determine efficiency of the BBa_K1321004 part. These tests were repeated three times to confirm the result.